Cargando…

High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis

Direct-acting antiviral (DAA) treatment for 8 weeks has a sustained virological response rate in adults with chronic hepatitis C. We have conducted a systematic review and meta-analysis to compare the efficacy and safety of the 8-week vs. 12/24-week DAA treatment in adolescents and children with CHC...

Descripción completa

Detalles Bibliográficos
Autores principales: Fu, Zuqiang, Dong, Chen, Ge, Zhijun, Wang, Chunhui, Zhang, Yun, Shen, Chao, Li, Jun, Zhu, Chuanlong, Wang, Yan, Huang, Peng, Yue, Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217461/
https://www.ncbi.nlm.nih.gov/pubmed/34169081
http://dx.doi.org/10.3389/fmed.2021.608760
_version_ 1783710594277310464
author Fu, Zuqiang
Dong, Chen
Ge, Zhijun
Wang, Chunhui
Zhang, Yun
Shen, Chao
Li, Jun
Zhu, Chuanlong
Wang, Yan
Huang, Peng
Yue, Ming
author_facet Fu, Zuqiang
Dong, Chen
Ge, Zhijun
Wang, Chunhui
Zhang, Yun
Shen, Chao
Li, Jun
Zhu, Chuanlong
Wang, Yan
Huang, Peng
Yue, Ming
author_sort Fu, Zuqiang
collection PubMed
description Direct-acting antiviral (DAA) treatment for 8 weeks has a sustained virological response rate in adults with chronic hepatitis C. We have conducted a systematic review and meta-analysis to compare the efficacy and safety of the 8-week vs. 12/24-week DAA treatment in adolescents and children with CHC. The PubMed, Web of Science, and Cochrane databases were searched for the relevant articles from January 1, 2017 to August 28, 2020 and further screened for literature reviews on April 1, 2021. Pool proportions with 95% CIs for SVR12 were summarized with fixed/random effects models using Freeman–Tukey double arcsine transformation. Subgroup analysis was used to explore the source of heterogeneity. Thirty-six relevant publications were identified. For adolescents aged 12–17 years old, the pooled SVR12 and AE rate were 99.4% (95% CI: 98.7–99.9) and 34.7% (95% CI: 31.9–37.6). No one discontinued treatment due to drug intolerance. In addition, the SVR12 adolescents treated for 12 and 8/24 weeks were 99.3% (95% CI: 98.4–99.9) and 100%, respectively. The pooled SVR12 rate, AEs, and SAEs for children younger than 12 years were 98.9% (95% CI: 97.3–99.8), 51.6% (95% CI: 47.0–56.2), and 1.1% (95% CI: 0.4–2.5), respectively. The most common AE was fatigue (28.4%). The SVR12 was 98.8% (95% CI: 97.1–99.8) and 100% for the pediatric patients treated for 12 weeks and 8/24 weeks, respectively. Taken together, DAAs are generally effective against CHC and well-tolerated by the adolescents and children. A treatment duration of 8 weeks is equally effective and safe as 12/24 weeks in this demographic group.
format Online
Article
Text
id pubmed-8217461
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82174612021-06-23 High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis Fu, Zuqiang Dong, Chen Ge, Zhijun Wang, Chunhui Zhang, Yun Shen, Chao Li, Jun Zhu, Chuanlong Wang, Yan Huang, Peng Yue, Ming Front Med (Lausanne) Medicine Direct-acting antiviral (DAA) treatment for 8 weeks has a sustained virological response rate in adults with chronic hepatitis C. We have conducted a systematic review and meta-analysis to compare the efficacy and safety of the 8-week vs. 12/24-week DAA treatment in adolescents and children with CHC. The PubMed, Web of Science, and Cochrane databases were searched for the relevant articles from January 1, 2017 to August 28, 2020 and further screened for literature reviews on April 1, 2021. Pool proportions with 95% CIs for SVR12 were summarized with fixed/random effects models using Freeman–Tukey double arcsine transformation. Subgroup analysis was used to explore the source of heterogeneity. Thirty-six relevant publications were identified. For adolescents aged 12–17 years old, the pooled SVR12 and AE rate were 99.4% (95% CI: 98.7–99.9) and 34.7% (95% CI: 31.9–37.6). No one discontinued treatment due to drug intolerance. In addition, the SVR12 adolescents treated for 12 and 8/24 weeks were 99.3% (95% CI: 98.4–99.9) and 100%, respectively. The pooled SVR12 rate, AEs, and SAEs for children younger than 12 years were 98.9% (95% CI: 97.3–99.8), 51.6% (95% CI: 47.0–56.2), and 1.1% (95% CI: 0.4–2.5), respectively. The most common AE was fatigue (28.4%). The SVR12 was 98.8% (95% CI: 97.1–99.8) and 100% for the pediatric patients treated for 12 weeks and 8/24 weeks, respectively. Taken together, DAAs are generally effective against CHC and well-tolerated by the adolescents and children. A treatment duration of 8 weeks is equally effective and safe as 12/24 weeks in this demographic group. Frontiers Media S.A. 2021-06-08 /pmc/articles/PMC8217461/ /pubmed/34169081 http://dx.doi.org/10.3389/fmed.2021.608760 Text en Copyright © 2021 Fu, Dong, Ge, Wang, Zhang, Shen, Li, Zhu, Wang, Huang and Yue. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Medicine
Fu, Zuqiang
Dong, Chen
Ge, Zhijun
Wang, Chunhui
Zhang, Yun
Shen, Chao
Li, Jun
Zhu, Chuanlong
Wang, Yan
Huang, Peng
Yue, Ming
High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis
title High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis
title_full High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis
title_fullStr High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis
title_full_unstemmed High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis
title_short High SVR12 With 8-Week Course of Direct-Acting Antivirals in Adolescents and Children With Chronic Hepatitis C: A Comprehensive Analysis
title_sort high svr12 with 8-week course of direct-acting antivirals in adolescents and children with chronic hepatitis c: a comprehensive analysis
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217461/
https://www.ncbi.nlm.nih.gov/pubmed/34169081
http://dx.doi.org/10.3389/fmed.2021.608760
work_keys_str_mv AT fuzuqiang highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis
AT dongchen highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis
AT gezhijun highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis
AT wangchunhui highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis
AT zhangyun highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis
AT shenchao highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis
AT lijun highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis
AT zhuchuanlong highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis
AT wangyan highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis
AT huangpeng highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis
AT yueming highsvr12with8weekcourseofdirectactingantiviralsinadolescentsandchildrenwithchronichepatitiscacomprehensiveanalysis